News
TEVA
20.94
-2.56%
-0.55
BRIEF-FDA Says Teva Pharmaceuticals USA's Isoniazid Tablets, USP, Tablet, 100 Mg Now Available- Website
Reuters · 9h ago
FDA Says Teva Pharmaceuticals USA's Ethinyl Estradiol; Norethindrone Tablet, Chewable Has Been Discontinued
Benzinga · 13h ago
Samsung Bioepis, Teva Enter License, Development, Commercialization Agreement For EPYSQLI
NASDAQ · 16h ago
Teva, Samsung Bioepis enter partnership for commercialization of EPYSQLI
TipRanks · 16h ago
TEVA: FINANCIAL TERMS OF AGREEMENT REMAIN CONFIDENTIAL.
Reuters · 16h ago
Drugmakers Raise the Prices on 583 Products to Start 2025
TipRanks · 1d ago
Pharma companies welcome new year with 583 drug price hikes so far
Seeking Alpha · 1d ago
Investing in Teva Pharmaceutical Industries (NYSE:TEVA) three years ago would have delivered you a 138% gain
Simply Wall St · 1d ago
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More
NASDAQ · 1d ago
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical
Benzinga · 1d ago
Catalyst settlement with Teva a positive event, says BofA
TipRanks · 1d ago
Catalyst stock climbs 15% on Firdapse litigation settlement
Seeking Alpha · 2d ago
Catalyst Pharmaceuticals up 18% after resumption following Teva settlement
TipRanks · 2d ago
Catalyst Pharmaceuticals reports settlement of Firdapse patent litigation with Teva
TipRanks · 2d ago
*Catalyst: Teva Gets License to Market Generic Firdapse Beginning February 2035
Dow Jones · 2d ago
Catalyst Pharmaceuticals Announces Settlement Of FIRDAPSE Patent Litigation With Teva Pharmaceuticals; Teva Will Not Market Its Generic Version Of FIRDAPSE In The U.S. Any Earlier Than February 25, 2035, If Approved By The FDA
Benzinga · 2d ago
*Catalyst Pharmaceuticals: Settlement Entered With Teva Pharmaceuticals in Firdapse Patent Litigation
Dow Jones · 2d ago
CATALYST PHARMACEUTICALS INC - PENGING FIRDAPSE PATENT LITIGATION AGAINST HETERO AND LUPIN ONGOING
Reuters · 2d ago
CATALYST PHARMACEUTICALS: UNDER AGREEMENT, TEVA WILL NOT MARKET GENERIC VERSION OF FIRDAPSE IN U.S. EARLIER THAN FEB 25, 2035, IF APPROVED BY U.S. FDA
Reuters · 2d ago
CATALYST PHARMACEUTICALS ANNOUNCES SETTLEMENT OF FIRDAPSE® (AMIFAMPRIDINE) PATENT LITIGATION WITH TEVA PHARMACEUTICALS
Reuters · 2d ago
More
Webull provides a variety of real-time TEVA stock news. You can receive the latest news about Teva Pharm through multiple platforms. This information may help you make smarter investment decisions.
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.